PSMD7: A Potential Drug Target and Biomarker for Proteasome-Mediated Processes

Target Name: PSMD7

NCBI ID: G5713

PSMD7

PSMD7: A Potential Drug Target and Biomarker for Proteasome-Mediated Processes

Introduction

Proteasomes, also known as intracellular granules, are complex organelles responsible for regulating protein degradation in eukaryotic cells. These structures consist of a protein-associated core and a surrounding membrane that is composed of multiple domains, including a catalytic subunit (eg, 26S subunit) and an ATPase domain. The 26S subunit is the most abundant subunit found in the proteasome and is responsible for the majority of protein-protein interactions that occur within the complex.

PSMD7, or proteasome (prosome, macropain) 26S subunit, non-ATPase, 7, is a protein that belongs to the family of cysteine-active proteinases (CAPs) and is highly conserved across various species, including humans. It is characterized by its catalytic subunit, its non-ATPase domain, and its unique 7-dimensional structure.

PSMD7 Functions as a Processive Enzyme

PSMD7 functions as a highly efficient enzyme, carrying out the process of protein degradation in the proteasome. Its catalytic subunit is responsible for the recognition and cleavage of target proteins, which are then released from the complex and degraded in the cytosol. The non-ATPase domain, which is rich in cysteine 鈥嬧?媟esidues, plays a crucial role in the electrostatic stability of the proteasome and contributes to its stability and catalytic activity.

PSMD7's 7-dimensional structure is highly conserved, with several key features being conserved across different species, including the presence of a nucleotide-binding domain (NBD) and a conserved hydrophilic core. The NBD is a critical region that plays a structural and functional role in the protein-protein interactions within the proteasome and is involved in regulating the assembly, disassembly, and activity of the complex.

PSMD7's conserved structure and unique functions make it an attractive drug target and biomarker for various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases.

PSMD7 as a Drug Target

PSMD7's unique functions and its conserved structure make it an attractive drug target for various diseases. The neurodegenerative disorder, Alzheimer's disease, is one of the most significant challenges in the development of new treatments for this disease. The normal function of the proteasome is disrupted in Alzheimer's disease, leading to the accumulation of misfolded proteins and the formation of aggregates that contribute to the disease's progression.

Preclinical studies have shown that PSMD7 can be a potential drug target for Alzheimer's disease, with several experimental approaches indicating that modifying PSMD7's activity may offer therapeutic benefits. For instance, overexpression of PSMD7 has been shown to reduce the formation of amyloid peptides in animal models of Alzheimer's disease, indicating that modifying PSMD7's activity may be an effective way to treat this disease.

PSMD7 may also be a useful biomarker for tracking the progression of Alzheimer's disease. The levels of PSMD7 have been shown to be decreased in the brains of individuals with Alzheimer's disease compared to age-matched control individuals. This suggests that PSMD7 may be a valuable diagnostic or predictive marker for Alzheimer's disease.

PSMD7 as a Biomarker

PSMD7's unique functions and its conserved structure make it an attractive biomarker for various diseases. The development of new diagnostic tools and biomarkers is a critical step in the development of new treatments for diseases. The studies described above demonstrate the potential of PSMD7 as a drug target and biomarker for various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases.

Conclusion

PSMD7 is a highly conserved protein that functions as a critical enzyme in the proteasome complex. Its unique 7-dimensional structure and catalytic subunit make it an attractive drug target and biomarker for various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. The studies described above demonstrate the potential of PSMD7 as a new therapeutic approach for the treatment of these diseases. Further research is needed to fully understand the role of PSMD7 in these diseases and to develop new treatments based on this protein.

Protein Name: Proteasome 26S Subunit, Non-ATPase 7

Functions: Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair

The "PSMD7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PSMD7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets